GB0919194D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0919194D0
GB0919194D0 GBGB0919194.1A GB0919194A GB0919194D0 GB 0919194 D0 GB0919194 D0 GB 0919194D0 GB 0919194 A GB0919194 A GB 0919194A GB 0919194 D0 GB0919194 D0 GB 0919194D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0919194.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lytix Biopharma AS
Original Assignee
Lytix Biopharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma AS filed Critical Lytix Biopharma AS
Priority to GBGB0919194.1A priority Critical patent/GB0919194D0/en
Publication of GB0919194D0 publication Critical patent/GB0919194D0/en
Priority to CN201080049560.6A priority patent/CN102762586B/zh
Priority to RU2015111706A priority patent/RU2676713C2/ru
Priority to DK10784830.1T priority patent/DK2496596T3/en
Priority to US13/505,625 priority patent/US8809280B2/en
Priority to NZ599791A priority patent/NZ599791A/en
Priority to PCT/GB2010/002024 priority patent/WO2011051692A1/en
Priority to CA2777749A priority patent/CA2777749C/en
Priority to RU2012121264/04A priority patent/RU2548905C2/ru
Priority to AU2010311186A priority patent/AU2010311186B2/en
Priority to EP10784830.1A priority patent/EP2496596B1/en
Priority to JP2012535924A priority patent/JP5810090B2/ja
Priority to BR112012010333-4A priority patent/BR112012010333B1/pt
Priority to PL10784830T priority patent/PL2496596T3/pl
Priority to KR1020127014266A priority patent/KR101730680B1/ko
Priority to ES10784830.1T priority patent/ES2621188T3/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0919194.1A 2009-11-02 2009-11-02 Compounds Ceased GB0919194D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds
ES10784830.1T ES2621188T3 (es) 2009-11-02 2010-11-02 Péptidos terapéuticos
PCT/GB2010/002024 WO2011051692A1 (en) 2009-11-02 2010-11-02 Therapeutic peptides
RU2012121264/04A RU2548905C2 (ru) 2009-11-02 2010-11-02 Терапевтические пептиды
DK10784830.1T DK2496596T3 (en) 2009-11-02 2010-11-02 THERAPEUTIC PEPTIDES
US13/505,625 US8809280B2 (en) 2009-11-02 2010-11-02 Therapeutic peptides
NZ599791A NZ599791A (en) 2009-11-02 2010-11-02 Therapeutic peptides
CN201080049560.6A CN102762586B (zh) 2009-11-02 2010-11-02 治疗肽
CA2777749A CA2777749C (en) 2009-11-02 2010-11-02 Therapeutic peptides comprising a disubstituted beta-amino acid for treating microbial infections or tumours
RU2015111706A RU2676713C2 (ru) 2009-11-02 2010-11-02 Терапевтические пептиды
AU2010311186A AU2010311186B2 (en) 2009-11-02 2010-11-02 Therapeutic peptides
EP10784830.1A EP2496596B1 (en) 2009-11-02 2010-11-02 Therapeutic peptides
JP2012535924A JP5810090B2 (ja) 2009-11-02 2010-11-02 治療用ペプチド
BR112012010333-4A BR112012010333B1 (pt) 2009-11-02 2010-11-02 Peptídeo ou derivado de aminoácido, seu uso, bem como formulação que os compreendem
PL10784830T PL2496596T3 (pl) 2009-11-02 2010-11-02 Peptydy terapeutyczne
KR1020127014266A KR101730680B1 (ko) 2009-11-02 2010-11-02 치료용 펩티드

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0919194.1A GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds

Publications (1)

Publication Number Publication Date
GB0919194D0 true GB0919194D0 (en) 2009-12-16

Family

ID=41435032

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0919194.1A Ceased GB0919194D0 (en) 2009-11-02 2009-11-02 Compounds

Country Status (14)

Country Link
US (1) US8809280B2 (https=)
EP (1) EP2496596B1 (https=)
JP (1) JP5810090B2 (https=)
KR (1) KR101730680B1 (https=)
CN (1) CN102762586B (https=)
AU (1) AU2010311186B2 (https=)
CA (1) CA2777749C (https=)
DK (1) DK2496596T3 (https=)
ES (1) ES2621188T3 (https=)
GB (1) GB0919194D0 (https=)
NZ (1) NZ599791A (https=)
PL (1) PL2496596T3 (https=)
RU (2) RU2548905C2 (https=)
WO (1) WO2011051692A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
DK3269809T3 (da) 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
US20190145962A1 (en) * 2016-04-14 2019-05-16 Tao Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
GB201705255D0 (en) * 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds
WO2018188761A1 (en) 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
WO2018225851A1 (ja) 2017-06-09 2018-12-13 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
EP3725796A4 (en) 2017-12-15 2021-09-15 Chugai Seiyaku Kabushiki Kaisha METHOD FOR MANUFACTURING PEPTIDE AND METHOD FOR PROCESSING BASES
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
JP7568510B2 (ja) 2018-11-30 2024-10-16 中外製薬株式会社 ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
KR20210139366A (ko) 2019-03-15 2021-11-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
CN110294793B (zh) * 2019-06-24 2023-10-27 合肥科生景肽生物科技有限公司 Sumo荧光探针及其制备方法
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
CN114790151B (zh) * 2022-02-14 2023-03-31 湖南省湘中制药有限公司 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法
AU2023413685A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342705A (en) 1979-11-23 1982-08-03 Monsanto Company Methylene thioethers
GR79206B (https=) 1982-06-03 1984-10-22 Montedison Spa
IT1161927B (it) 1983-03-31 1987-03-18 Montedison Spa Furano-derivati ad attivita' fungicida
DK523288A (da) 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
CA1328333C (en) 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
CA2088195A1 (en) 1990-08-31 1992-03-01 David C. Horwell Cholecystokinin antagonists, their preparation and therapeutic use
US5593967A (en) 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
US5387671A (en) 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
US5885782A (en) 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
DK0906094T3 (da) 1996-01-02 2003-10-20 Aventis Pharma Inc Substituerede N-[(aminoiminomethyl- eller aminomethyl)phenyl]propylamider
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
DE102006018080A1 (de) * 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide
US7960339B2 (en) * 2006-07-10 2011-06-14 Österreichische Akademie der Wissenschaften Antimicrobial peptides
GB0724951D0 (en) * 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
ATE482186T1 (de) * 2008-03-18 2010-10-15 Univ Dresden Tech Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion

Also Published As

Publication number Publication date
ES2621188T3 (es) 2017-07-03
RU2676713C2 (ru) 2019-01-10
CN102762586A (zh) 2012-10-31
CN102762586B (zh) 2016-10-05
PL2496596T3 (pl) 2017-08-31
US8809280B2 (en) 2014-08-19
RU2548905C2 (ru) 2015-04-20
RU2012121264A (ru) 2013-12-10
JP2013509389A (ja) 2013-03-14
EP2496596B1 (en) 2017-01-11
AU2010311186B2 (en) 2015-09-24
DK2496596T3 (en) 2017-04-03
BR112012010333A2 (pt) 2016-03-29
AU2010311186A1 (en) 2012-05-31
EP2496596A1 (en) 2012-09-12
JP5810090B2 (ja) 2015-11-11
RU2015111706A3 (https=) 2018-10-29
KR101730680B1 (ko) 2017-04-26
US20130035296A1 (en) 2013-02-07
CA2777749A1 (en) 2011-05-05
KR20120104986A (ko) 2012-09-24
NZ599791A (en) 2014-10-31
WO2011051692A1 (en) 2011-05-05
CA2777749C (en) 2019-08-06
RU2015111706A (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
IL213992A0 (en) Pro-neurogenic compounds
EP2393493A4 (en) LINKS
IL219248A0 (en) Compounds
GB0907515D0 (en) Compounds
GB0914856D0 (en) Compounds
GB0919194D0 (en) Compounds
GB0915892D0 (en) Compounds
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
ZA201200093B (en) 3-phenoxymethylpyrrolidine compounds
GB0919594D0 (en) Compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
EP2443115A4 (en) COMPOUNDS
GB0906853D0 (en) Compounds
GB0903492D0 (en) Compounds
GB0908942D0 (en) Compounds
GB0908941D0 (en) Compounds
GB0903948D0 (en) Compounds
GB0906854D0 (en) Compounds
GB0904746D0 (en) Compounds
GB0906378D0 (en) Compounds
GB0905932D0 (en) Compounds
GB0910008D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)